Universe Pharmaceuticals (NASDAQ:UPC) Stock Price Down 2.4% – Time to Sell?

Universe Pharmaceuticals INC (NASDAQ:UPC)’s stock price fell 2.4% during mid-day trading on Friday . The company traded as low as $2.87 and last traded at $3.28. 16,852 shares changed hands during trading, an increase of 199% from the average session volume of 5,629 shares. The stock had previously closed at $3.36.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Universe Pharmaceuticals in a report on Tuesday, February 3rd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

Universe Pharmaceuticals Stock Down 2.4%

The stock’s fifty day moving average price is $2.81 and its 200-day moving average price is $3.80.

Universe Pharmaceuticals (NASDAQ:UPC) last posted its quarterly earnings data on Thursday, January 29th. The company reported $0.69 earnings per share (EPS) for the quarter. The business had revenue of $8.92 billion during the quarter.

About Universe Pharmaceuticals

Universe Pharmaceuticals, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.

The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action.